Biogen Inc
NASDAQ:BIIB

Watchlist Manager
Biogen Inc Logo
Biogen Inc
NASDAQ:BIIB
Watchlist
Price: 158.605 USD 0.38% Market Closed
Market Cap: 23.1B USD
Have any thoughts about
Biogen Inc?
Write Note

Intrinsic Value

The intrinsic value of one BIIB stock under the Base Case scenario is 202.048 USD. Compared to the current market price of 158.605 USD, Biogen Inc is Undervalued by 22%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BIIB Intrinsic Value
202.048 USD
Undervaluation 22%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Biogen Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for BIIB cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about BIIB?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Biogen Inc

Provide an overview of the primary business activities
of Biogen Inc.

What unique competitive advantages
does Biogen Inc hold over its rivals?

What risks and challenges
does Biogen Inc face in the near future?

Has there been any significant insider trading activity
in Biogen Inc recently?

Summarize the latest earnings call
of Biogen Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Biogen Inc.

Provide P/S
for Biogen Inc.

Provide P/E
for Biogen Inc.

Provide P/OCF
for Biogen Inc.

Provide P/FCFE
for Biogen Inc.

Provide P/B
for Biogen Inc.

Provide EV/S
for Biogen Inc.

Provide EV/GP
for Biogen Inc.

Provide EV/EBITDA
for Biogen Inc.

Provide EV/EBIT
for Biogen Inc.

Provide EV/OCF
for Biogen Inc.

Provide EV/FCFF
for Biogen Inc.

Provide EV/IC
for Biogen Inc.

Show me price targets
for Biogen Inc made by professional analysts.

What are the Revenue projections
for Biogen Inc?

How accurate were the past Revenue estimates
for Biogen Inc?

What are the Net Income projections
for Biogen Inc?

How accurate were the past Net Income estimates
for Biogen Inc?

What are the EPS projections
for Biogen Inc?

How accurate were the past EPS estimates
for Biogen Inc?

What are the EBIT projections
for Biogen Inc?

How accurate were the past EBIT estimates
for Biogen Inc?

Compare the revenue forecasts
for Biogen Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Biogen Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Biogen Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Biogen Inc compared to its peers.

Compare the P/E ratios
of Biogen Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Biogen Inc with its peers.

Analyze the financial leverage
of Biogen Inc compared to its main competitors.

Show all profitability ratios
for Biogen Inc.

Provide ROE
for Biogen Inc.

Provide ROA
for Biogen Inc.

Provide ROIC
for Biogen Inc.

Provide ROCE
for Biogen Inc.

Provide Gross Margin
for Biogen Inc.

Provide Operating Margin
for Biogen Inc.

Provide Net Margin
for Biogen Inc.

Provide FCF Margin
for Biogen Inc.

Show all solvency ratios
for Biogen Inc.

Provide D/E Ratio
for Biogen Inc.

Provide D/A Ratio
for Biogen Inc.

Provide Interest Coverage Ratio
for Biogen Inc.

Provide Altman Z-Score Ratio
for Biogen Inc.

Provide Quick Ratio
for Biogen Inc.

Provide Current Ratio
for Biogen Inc.

Provide Cash Ratio
for Biogen Inc.

What is the historical Revenue growth
over the last 5 years for Biogen Inc?

What is the historical Net Income growth
over the last 5 years for Biogen Inc?

What is the current Free Cash Flow
of Biogen Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Biogen Inc.

Business Breakdown

Biogen Inc. is a renowned biotechnology company that has carved out a niche in the development and delivery of groundbreaking therapies for neurological diseases. Founded in 1978, the company has focused on addressing some of the most challenging and complex health conditions, particularly multiple sclerosis (MS) and Alzheimer’s disease. With a robust pipeline of innovative treatments, Biogen aims to improve the lives of individuals affected by debilitating neurological disorders. Its flagship products, including drugs such as Tecfidera and Avonex, have notably solidified Biogen's reputation as a leader in MS treatment, contributing significantly to its revenue stream and positioning the com...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Biogen Inc

Current Assets 6.8B
Cash & Short-Term Investments 1.7B
Receivables 2B
Other Current Assets 3.1B
Non-Current Assets 21.5B
Long-Term Investments 631.4m
PP&E 3.6B
Intangibles 16.3B
Other Non-Current Assets 968.7m
Current Liabilities 5.4B
Accounts Payable 422.7m
Accrued Liabilities 1.7B
Other Current Liabilities 3.3B
Non-Current Liabilities 6.5B
Long-Term Debt 4.5B
Other Non-Current Liabilities 2B
Efficiency

Earnings Waterfall
Biogen Inc

Revenue
9.6B USD
Cost of Revenue
-2.3B USD
Gross Profit
7.3B USD
Operating Expenses
-4.8B USD
Operating Income
2.5B USD
Other Expenses
-875.5m USD
Net Income
1.6B USD

Free Cash Flow Analysis
Biogen Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In the third quarter, Biogen reported $2.5 billion in revenue, reflecting a 3% decline year-over-year. Despite challenges in the MS product line, non-GAAP operating income rose by 4%. The company raised its 2024 non-GAAP EPS guidance to $16.10-$16.60, indicating a projected growth of about 11% from the previous year. Notably, rare disease revenues grew 10% to $495 million, driven by strong demand for SKYCLARYS, while ZURZUVAE saw a 49% increase in revenue. The anticipated rollout of subcutaneous formulations and stronger sales strategies may bolster future growth. The financial health remains solid with $1.7 billion in cash and a focus on sustainable growth strategies.

What is Earnings Call?
Fundamental Scores

BIIB Profitability Score
Profitability Due Diligence

Biogen Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive Operating Income
Positive Net Income
58/100
Profitability
Score

Biogen Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

BIIB Solvency Score
Solvency Due Diligence

Biogen Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Average Altman Z-Score
Short-Term Solvency
58/100
Solvency
Score

Biogen Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BIIB Price Targets Summary
Biogen Inc

Wall Street analysts forecast BIIB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BIIB is 253.572 USD with a low forecast of 181.8 USD and a high forecast of 359.1 USD.

Lowest
Price Target
181.8 USD
15% Upside
Average
Price Target
253.572 USD
60% Upside
Highest
Price Target
359.1 USD
126% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BIIB?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for BIIB is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

BIIB Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

BIIB News

Other Videos

Profile

Biogen Inc Logo
Biogen Inc

Country

United States of America

Industry

Biotechnology

Market Cap

23B USD

Dividend Yield

0%

Description

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 9,610 full-time employees. The company is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. The company has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. The company also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA; OCREVUS; and other potential anti-CD20 therapies, including mosunetuzumab.

Contact

MASSACHUSETTS
Cambridge
225 Binney St
+17814642000.0
www.biogen.com

IPO

1991-09-17

Employees

9 610

Officers

President, CEO & Director
Mr. Christopher A. Viehbacher
Executive VP & CFO
Mr. Michael R. McDonnell CPA
Head of Pharmaceutical Operations & Technology
Ms. Nicole Murphy
Executive VP & Chief Legal Officer
Ms. Susan H. Alexander Esq.
Head of Global Product Strategy & Commercialization
Mr. Rachid Izzar
Senior VP & Chief Accounting Officer
Ms. Robin C. Kramer
Show More
Head of Investor Relations
Dr. Stephen Amato
Chief Communication Officer & Head of Corporate Affairs
Ms. Natacha Gassenbach
Executive VP & Head of Corporate Development
Mr. Adam Keeney Ph.D.
Executive VP & Chief Human Resources Officer
Dr. Ginger Gregory Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one BIIB stock?

The intrinsic value of one BIIB stock under the Base Case scenario is 202.048 USD.

Is BIIB stock undervalued or overvalued?

Compared to the current market price of 158.605 USD, Biogen Inc is Undervalued by 22%.

Back to Top